Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective

Susan C Bolge1 Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, USACorrespondence[email protected]

Amir Goren2 Health Outcomes Practice, Kantar Health, New York, NY, USA

Neeta Tandon1 Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Horsham, PA, USA

Pages 121-131 | Published online: 20 Jan 2015

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

YoungAKoduriGExtra-articular manifestations and complications of rheumatoid arthritisBest Pract Res Clin Rheumatol200721590792717870035
PubMed Web of Science ®Google Scholar
AletahaDNeogiTSilmanAJ2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeArthritis Rheum20106292569258120872595
PubMed Web of Science ®Google Scholar
KvienTKEpidemiology and burden of illness of rheumatoid arthritisPharmacoeconomics2004222 Suppl 111215157000
PubMed Web of Science ®Google Scholar
SalaffiFCarottiMGaspariniSIntorciaMGrassiWThe health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy peopleHealth Qual Life Outcomes200972519296831
PubMed Web of Science ®Google Scholar
DavidGTandonNWatersHCGunnarssonCKavanaughARheumatoid arthritis and total hip and knee replacement: impact of biologicsAm J Pharm Benefits2014
Google Scholar
SokkaTAbelsonBPincusTMortality in rheumatoid arthritis: 2008 updateClin Exp Rheumatol2008265 Suppl 51S35S6119026144
PubMed Web of Science ®Google Scholar
SinghJAFurstDEBharatA2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritisArthritis Care Res (Hoboken)201264562563922473917
PubMed Web of Science ®Google Scholar
TakPPKaldenJRAdvances in rheumatology: new targeted therapeuticsArthritis Res Ther201113Suppl 1S521624184
PubMed Web of Science ®Google Scholar
BreedveldFCCombeBUnderstanding emerging treatment paradigms in rheumatoid arthritisArthritis Res Ther201113Suppl 1S321624182
PubMedGoogle Scholar
De GeestSSabatéEAdherence to long-term therapies: evidence for actionEur J Cardiovasc Nurs20032432314667488
PubMedGoogle Scholar
YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm200915972874019954264
PubMed Web of Science ®Google Scholar
BlomMKievitWFransenJThe reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisJ Rheumatol200936102171217719723902
PubMed Web of Science ®Google Scholar
InghamMReedGBolceRPatterns of anti-TNF treatment in the CORRONA registry: observed responses to maintenance, switching and discontinuation [abstract]Ann Rheum Dis201170Suppl 3415
Google Scholar
MarkensonJAGibofskyAPalmerWRPersistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJ Rheumatol20113871273128121572150
PubMed Web of Science ®Google Scholar
CurkendallSPatelVGleesonMCampbellRSZagariMDuboisRCompliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?Arthritis Rheum200859101519152618821651
PubMed Web of Science ®Google Scholar
BartonJLImbodenJGrafJGliddenDYelinEHSchillingerDPatient-physician discordance in assessments of global disease severity in rheumatoid arthritisArthritis Care Res (Hoboken)201062685786420535797
PubMed Web of Science ®Google Scholar
CurtisJRHobarCHansbroughKInjection-site burning and stinging in patients with rheumatoid arthritis using injectable biologicsCurr Med Res Opin201127717821091097
PubMed Web of Science ®Google Scholar
da SilvaJARamiroSPedroSRodriguesAVasconcelosJCBenito-GarciaEPatients- and physicians-priorities for improvement. The case of rheumatic diseasesActa Reumatol Port201035219219920734542
PubMed Web of Science ®Google Scholar
Enbrel^® (etanercept) [package insert]Thousand Oaks, CAImmunex Corporation2013
Google Scholar
Humira^® (adalimumab) [package insert]North Chicago, ILAbbVie, Inc2014
Google Scholar
Cimzia^® (certolizumab) [package insert]Smyrna, GAUCB, Inc2013
Google Scholar
Simponi^® (golimumab) [package insert]Horsham, PAJanssen Biotech, Inc2014
Google Scholar
FleischmannRYocumDDoes safety make a difference in selecting the right TNF antagonist?Arthritis Res Ther20046Suppl 2S12S1815228616
PubMed Web of Science ®Google Scholar
FraenkelLBogardusSConcatoJFelsonDRisk communication in rheumatoid arthritisJ Rheumatol200330344344812610798
PubMed Web of Science ®Google Scholar
van den BemtBJvan LankveldWGHow can we improve adherence to therapy by patients with rheumatoid arthritis?Nat Clin Pract Rheumatol200731268118037928
PubMedGoogle Scholar
BeckMSearching for Side Effects [webpage on the Internet]New York, NY: The Wall Street Journal2012 Available from: http://online.wsj.com/article/SB10001424052970203920204577193052426275904.html?KEYWORDS=Searching+for+Side+EffectsAccessed February 6, 2013
Google Scholar
TanakaYHirataSIs it possible to withdraw biologics from therapy in rheumatoid arthritis?Clin Ther201335122028203524290736
PubMed Web of Science ®Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date